What's Inside

College Links









Make a Gift box


  Home > Current Clinical Trials > Oncology



Welcome to the Oncology Clinical Trials Page!

The following studies are currently recruiting patients. Click on the study name for full information below:

SRCBST: dose-finding for a ligand targeted toxin to treat hemangiosarcoma 

To find out how to donate samples for veterinary oncology research, see Modiano Lab Study Info.

SRCBST: dose-finding for a ligand targeted toxin to treat hemangiosarcoma 

Current Status: Active and enrolling
Principal Investigator: Jaime Modiano, VMD, PhD,
Contacts: Dr. Modiano:
Amber Winter, study technician: 612-624-1352 or
Oncology service at 612-626-8387 (main VMC number) 

News! Results were presented on April 20, 2015 at the American Association for Cancer Research conference in Philadelphia, PA from the first 21 dogs with hemangiosarcoma treated in the SRCBST trial showing that the drug is safe and doubles the expected survival time.  This significant gain in the treatment for this disease is encouraging, and it strengthens our resolve to continue our efforts to improve survival and maintain quality of life for dogs with hemangiosarcoma. See the poster here.

The study: Hemangiosarcoma is a type of sarcoma that is difficult to treat because of its aggressive behavior and rapid progression after diganosis. SRCBST is a sarcoma bispecific targeted toxin that has been shown to be safe in other species and that it can kill hemangiosarcoma cells in the laboratory. This is a dose-finding trial to determine the safest dose of SRCBST which is still effective. Results of this study will provide informaiton to develop a therapy for both dogs and humans with this incurable disease.

Eligible dogs:

  • Hemangiosarcoma restricted to the spleen, which will be treated by removal of the spleen prior to enrollment in the study
  • Weight more than 15 lbs
  • No evidence of metastasis on radiographs, ultrasound
  • Adequate supply of blood cells
  • No concurrent kidney, liver, heart disease, or problems with blood clotting
  • No previous chemotherapy
  • OK to be on prednisone or Non-steroidal anti-inflammatory drugs (NSAIDS)


  • PET-CT (optional but desired): A week to two weeks after surgery, drop off dog for the day and overnight. We transport to imaging center on the Mpls campus (Center for Magnetic Resonance Research), provide anesthesia and stay with the dog during procedure then return to VMC. Dogs stay overnight due to radioactive contrast used for the PET-CT, needs to be eliminated before the dog can go home.
  • Wednesday, SRCBST treatment 1: drop off for the day, we collect blood, give first dose of SRCBST through intravenous catheter, collect small amounts of blood for 3 hours following to help us assess the pharmacokinetics and drug distribution
  • Friday, SRCBST treatment 2: Same as Day 1, drop off for the day
  • Monday, SRCBST treatment 3: Same as Day 1, drop off for the day
  • Weds. Day 8, Recheck
  • Day 21 recheck, begin chemotherapy, possible 2nd PET-CT (see above)
  • Chemotherapy continues for total of 5 doses, every 3 weeks

Costs of the study: Owners pay for splenectomy surgery and initial oncology exam (estimated $3,800-$4,000 for surgery and $188 for exam). Once enrolled the study pays for prescreening chest x-rays, abdominal ultrasound, bloodwork, urinalysis, PET-CT, all visits listed above. This is a $8,500 - $9,560 value. In addition, the study will cover up to $5,000 in chemotherapy costs (covers most if not all of chemotherapy depending upon the size of the dog).

To enroll or learn more about the study, please contact Amber Winter or Dr. Modiano (above).

Return to top

For more information on cancer research at the College of Veterinary Medicine, please go to the Animal Cancer Care and Research site.

For information on the Oncology department at the Veterinary Medical Center, go here.

You may also Contact Us at the CIC.



Notice of Privacy Practices